Repligen Corporation (NASDAQ:RGEN) – Jefferies Group boosted their Q3 2017 earnings estimates for shares of Repligen Corporation in a report released on Friday. Jefferies Group analyst B. Couillard now expects that the biotechnology company will earn $0.15 per share for the quarter, up from their prior estimate of $0.13. Jefferies Group currently has a “Hold” rating and a $40.00 target price on the stock. Jefferies Group also issued estimates for Repligen Corporation’s Q4 2017 earnings at $0.12 EPS, FY2017 earnings at $0.61 EPS, Q2 2018 earnings at $0.19 EPS, Q3 2018 earnings at $0.18 EPS, Q4 2018 earnings at $0.18 EPS, FY2018 earnings at $0.72 EPS and FY2019 earnings at $0.88 EPS.

RGEN has been the subject of a number of other reports. Janney Montgomery Scott boosted their target price on shares of Repligen Corporation from $42.00 to $47.00 in a report on Friday, June 23rd. First Analysis restated an “equal weight” rating and set a $40.00 price objective on shares of Repligen Corporation in a report on Friday, April 21st. Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a report on Thursday, May 11th. BidaskClub downgraded shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. Finally, William Blair assumed coverage on shares of Repligen Corporation in a report on Friday, July 21st. They set an “outperform” rating on the stock. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $41.20.

ILLEGAL ACTIVITY WARNING: “Q3 2017 EPS Estimates for Repligen Corporation (NASDAQ:RGEN) Lifted by Analyst” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/07/q3-2017-eps-estimates-for-repligen-corporation-nasdaqrgen-lifted-by-analyst.html.

Shares of Repligen Corporation (NASDAQ:RGEN) opened at 41.53 on Monday. Repligen Corporation has a 1-year low of $26.16 and a 1-year high of $46.81. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 109.58 and a beta of 1.30. The firm’s 50-day moving average is $41.28 and its 200-day moving average is $36.10.

Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.05. The business had revenue of $32.40 million during the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 10.20%. Repligen Corporation’s revenue was up 11.0% compared to the same quarter last year. During the same period last year, the business earned $0.16 EPS.

Institutional investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. bought a new position in Repligen Corporation during the first quarter valued at about $103,000. Victory Capital Management Inc. increased its position in Repligen Corporation by 76.6% in the first quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 1,475 shares during the period. State of Alaska Department of Revenue increased its position in Repligen Corporation by 2.2% in the first quarter. State of Alaska Department of Revenue now owns 3,740 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 80 shares during the period. JPMorgan Chase & Co. increased its position in Repligen Corporation by 31.9% in the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 908 shares during the period. Finally, US Bancorp DE increased its position in Repligen Corporation by 1.2% in the second quarter. US Bancorp DE now owns 4,629 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 54 shares during the period. Hedge funds and other institutional investors own 98.57% of the company’s stock.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Earnings History and Estimates for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.